EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Circulating biomarkers for management of cancer therapeutics-related cardiac dysfunction

Claire Tonry iD, Adam Russell-Hallinan iD, Claire McCune, Patrick Collier iD, Mark Harbinson iD, Lana Dixon, Chris J Watson iD

Cardiovascular Research · 2023

DOI: 10.1093/cvr/cvac087 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cardiovascular Research, 2023. Verfasst von Claire Tonry und 6 weiteren Autor:innen. Beteiligte Einrichtung: Wellcome-Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queens University Belfast, Northern Irel…. Hauptthemen laut MEDLINE: Antineoplastic Agents, Heart Diseases, Neoplasms. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 156 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer therapeutics-related cardiac dysfunction (CTRCD) has emerged as a major cause of morbidity and mortality in cancer survivors. Effective clinical management of CTRCD is impeded by a lack of sensitive diagnostic and prognostic strategies. Circulating molecular markers could potentially address this need as they are often indicative of cardiac stress before cardiac damage can be detected clinically. A growing understanding of the underlying physiological mechanisms for CTRCD has inspired research efforts to identify novel pathophysiologically relevant biomarkers that may also guide development of cardio-protective therapeutic approaches. The purpose of this review is to evaluate current circulating biomarkers of cardiac stress and their potential role in diagnosis and management of CTRCD. We also discuss some emerging avenues for CTRCD-focused biomarker investigations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsHeart DiseasesNeoplasmsHumansCardiotoxicityBiomarkersEchocardiography

Stichwörter der Autor:innen

BiomarkersCardiooncologyCardiotoxicityChemotherapy

Substanzen

Antineoplastic AgentsBiomarkers

Autor:innen und Institutionen

  • Wellcome-Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queens University Belfast, Northern Ireland, UK.
  • Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, USA.
  • Belfast Health and Social Care Trust, Belfast, Northern Ireland, UK.

ORCID-Profile: Claire Tonry, Adam Russell-Hallinan, Patrick Collier, Mark Harbinson, Chris J Watson

Zitieren

APA

Tonry, C., Russell-Hallinan, A., McCune, C., Collier, P., Harbinson, M., Dixon, L., & Watson, C. J. (2023). Circulating biomarkers for management of cancer therapeutics-related cardiac dysfunction. Cardiovascular Research. https://doi.org/10.1093/cvr/cvac087

Vancouver

Tonry C, Russell-Hallinan A, McCune C, Collier P, Harbinson M, Dixon L, et al. Circulating biomarkers for management of cancer therapeutics-related cardiac dysfunction. Cardiovascular Research. 2023. doi:10.1093/cvr/cvac087

BibTeX
@article{Tonry2023,
  author = {Tonry, Claire and Russell-Hallinan, Adam and McCune, Claire and Collier, Patrick and Harbinson, Mark and Dixon, Lana and Watson, Chris J},
  title = {Circulating biomarkers for management of cancer therapeutics-related cardiac dysfunction},
  journal = {Cardiovascular Research},
  year = {2023},
  doi = {10.1093/cvr/cvac087}
}
Kostenlos starten →